A phase 2, open-label, safety and efficacy study of Panzem nanocrystal colloidal dispersion administered orally in patients with recurrent or resistant epithelial ovarian cancer
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2014
At a glance
- Drugs 2-methoxyestradiol (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors CASI Pharmaceuticals; EntreMed
- 25 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov.
- 13 Mar 2008 Planned patient number (18) added from Clinicaltrials.gov.
- 13 Mar 2008 The expected completion date for this trial is now 1 Aug 2008, according to ClinicalTrials.gov.